Loading...

Celsion

DB:CBOC
Snowflake Description

High growth potential with adequate balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CBOC
DB
$46M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The last earnings update was 27 days ago. More info.


Add to Portfolio Compare Print
CBOC Share Price and Events
7 Day Returns
5.8%
DB:CBOC
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
13.5%
DB:CBOC
-5.6%
DE Biotechs
-4.5%
DE Market
CBOC Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Celsion (CBOC) 5.8% 19.4% 10.5% 13.5% -88.8% -93.6%
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • CBOC outperformed the Biotechs industry which returned -5.6% over the past year.
  • CBOC outperformed the Market in Germany which returned -4.5% over the past year.
Price Volatility
CBOC
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Celsion undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Celsion. This is due to cash flow or dividend data being unavailable. The share price is €2.077.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Celsion's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Celsion's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CBOC PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.68
NasdaqCM:CLSN Share Price ** NasdaqCM (2019-04-25) in USD $2.27
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Celsion.

DB:CBOC PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:CLSN Share Price ÷ EPS (both in USD)

= 2.27 ÷ -0.68

-3.36x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celsion is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Celsion is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Celsion's expected growth come at a high price?
Raw Data
DB:CBOC PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.36x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
48.1%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Celsion, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Celsion's assets?
Raw Data
DB:CBOC PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $1.11
NasdaqCM:CLSN Share Price * NasdaqCM (2019-04-25) in USD $2.27
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:CBOC PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:CLSN Share Price ÷ Book Value per Share (both in USD)

= 2.27 ÷ 1.11

2.05x

* Primary Listing of Celsion.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Celsion is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Celsion's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Celsion has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Celsion expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
48.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Celsion expected to grow at an attractive rate?
  • Celsion's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Celsion's earnings growth is expected to exceed the Germany market average.
  • Celsion's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CBOC Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CBOC Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 48.1%
DB:CBOC Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 59.5%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CBOC Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CBOC Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 110 55 1
2022-12-31 68 28 2
2021-12-31 22 -14 2
2020-12-31 0 -22 2
2019-12-31 1 -18 1
DB:CBOC Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 1 -7 -12
2018-09-30 1 -17 -22
2018-06-30 1 -18 -23
2018-03-31 1 -18 -20
2017-12-31 1 -17 -21
2017-09-30 1 -17 -21
2017-06-30 1 -17 -22
2017-03-31 1 -17 -21
2016-12-31 1 -18 -22
2016-09-30 1 -18 -22
2016-06-30 1 -18 -20
2016-03-31 1 -20 -21

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Celsion's earnings are expected to grow significantly at over 20% yearly.
  • Celsion's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CBOC Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Celsion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CBOC Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 1.16 1.16 1.16 1.00
2022-12-31 1.07 1.81 0.32 2.00
2021-12-31 -0.37 -0.16 -0.58 2.00
2020-12-31 -0.78 -0.55 -1.00 2.00
2019-12-31 -0.89 -0.89 -0.89 1.00
DB:CBOC Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.68
2018-09-30 -1.31
2018-06-30 -1.72
2018-03-31 -1.73
2017-12-31 -2.72
2017-09-30 -4.89
2017-06-30 -5.58
2017-03-31 -11.59
2016-12-31 -11.89
2016-09-30 -12.58
2016-06-30 -11.96
2016-03-31 -13.08

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Celsion will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Celsion's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Celsion has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Celsion performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Celsion's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Celsion does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Celsion's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Celsion's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Celsion's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Celsion Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CBOC Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.50 -11.88 9.70
2018-09-30 0.50 -22.04 8.77 12.73
2018-06-30 0.50 -23.06 7.98 13.89
2018-03-31 0.50 -20.06 6.09 12.34
2017-12-31 0.50 -20.75 5.89
2017-09-30 0.50 -21.46 5.93 13.49
2017-06-30 0.50 -22.20 6.25 14.37
2017-03-31 0.50 -21.50 6.13 14.66
2016-12-31 0.50 -22.05 6.53 14.62
2016-09-30 0.50 -22.17 6.26 14.71
2016-06-30 0.50 -20.03 6.24 13.36
2016-03-31 0.50 -21.17 6.52 13.59
2015-12-31 0.50 -22.46 6.69 14.66
2015-09-30 0.50 -23.40 7.39 16.14
2015-06-30 0.50 -26.08 7.96 16.98
2015-03-31 0.50 -27.08 8.46 16.58
2014-12-31 0.50 -25.49 8.86 14.97
2014-09-30 0.50 -22.99 8.10 11.66
2014-06-30 0.50 -20.12 7.45 10.20
2014-03-31 0.50 -13.02 7.09 9.05
2013-12-31 0.50 -12.85 6.55 9.36
2013-09-30 0.38 -17.16 6.82 10.92
2013-06-30 0.25 -19.11 6.85 12.19
2013-03-31 0.13 -25.63 6.49 14.28
2012-12-31 -26.57 6.37 15.77
2012-09-30 0.00 -24.43 5.83 17.48
2012-06-30 0.00 -24.80 5.82 19.36

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Celsion has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Celsion has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Celsion improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Celsion's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Celsion has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Celsion's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Celsion's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Celsion is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Celsion's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Celsion's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 3x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Celsion Company Filings, last reported 3 months ago.

DB:CBOC Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 20.86 9.42 27.61
2018-09-30 15.13 9.32 21.95
2018-06-30 19.15 9.22 26.20
2018-03-31 23.61 0.00 20.70
2017-12-31 26.70 0.00 24.17
2017-09-30 5.29 0.00 2.69
2017-06-30 6.65 0.00 3.63
2017-03-31 6.11 1.47 4.47
2016-12-31 6.73 2.56 4.30
2016-09-30 10.57 3.59 8.70
2016-06-30 16.51 4.58 14.47
2016-03-31 15.31 5.52 14.31
2015-12-31 20.39 6.42 20.07
2015-09-30 25.08 7.32 24.35
2015-06-30 29.11 8.15 30.73
2015-03-31 26.70 8.94 30.01
2014-12-31 32.83 9.71 36.86
2014-09-30 38.92 9.59 43.61
2014-06-30 45.36 9.64 49.77
2014-03-31 40.56 5.00 51.86
2013-12-31 31.52 5.01 42.87
2013-09-30 29.14 4.29 45.21
2013-06-30 32.99 4.75 48.73
2013-03-31 32.30 5.06 45.57
2012-12-31 11.96 5.07 23.03
2012-09-30 13.02 5.09 22.55
2012-06-30 14.58 5.10 24.00
  • Celsion's level of debt (45.1%) compared to net worth is high (greater than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (15.8% vs 45.1% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Celsion has sufficient cash runway for more than 3 years based on current free cash flow.
  • Celsion has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -12.2% each year.
X
Financial health checks
We assess Celsion's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Celsion has a total score of 4/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Celsion's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Celsion dividends.
If you bought €2,000 of Celsion shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Celsion's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Celsion's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CBOC Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CBOC Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Celsion has not reported any payouts.
  • Unable to verify if Celsion's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Celsion's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Celsion has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Celsion's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Celsion afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Celsion has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Celsion's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Michael Tardugno
COMPENSATION $2,950,091
AGE 67
TENURE AS CEO 12.3 years
CEO Bio

Mr. Michael H. Tardugno has been the Chief Executive Officer and President of Celsion Corporation since January 3, 2007 and has been its Executive Chairman since October 7, 2014. Mr. Tardugno has an extensive experience in Pharmaceutical industry leadership. He served as Senior Vice President and General Manager of Mylan Laboratories Inc., since February 2005. From 1998 to 2005, he served as an Executive Vice President and a Founding member of Management of Songbird Hearing, Inc., where he forged a number of significant agreements with major US and International partners in the development and commercialization of the world's first disposable hearing aid. Mr. Tardugno served as a Senior Vice President of ConvaTec, a division of Bristol-Myers Squibb from 1996 to 1998 and its Vice President of Technology Development & Manufacturing of Bausch & Lomb from 1989 to 1995. He started his career with Abbott Laboratories holding positions in pharmaceutical operations, principally as plant manager for its Ross Laboratories Division nutritional business. Mr. Tardugno has been a Director at Celsion Corporation since January 03, 2007. He served as a Director of Theranostics Health, LLC. Mr. Tardugno holds a B.S. in Biology and Chemistry minor from St. Bonaventure University and attended Program for Management Development from Harvard Business School.

CEO Compensation
  • Michael's compensation has increased whilst company is loss making.
  • Michael's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Celsion management team in years:

8.8
Average Tenure
60
Average Age
  • The average tenure for the Celsion management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Michael Tardugno

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
67
TENURE
12.3 yrs

Jeff Church

TITLE
CFO, Executive VP & Corporate Secretary
COMPENSATION
$1M
AGE
61
TENURE
8.8 yrs

Khursheed Anwer

TITLE
Executive VP & Chief Scientific Officer
COMPENSATION
$667K
AGE
58
TENURE
4.8 yrs

Nicholas Borys

TITLE
Executive VP & Chief Medical Officer
COMPENSATION
$1M
AGE
59
TENURE
11.5 yrs

Timothy Tumminello

TITLE
Chief Accounting Officer & Controller
COMPENSATION
$138K
AGE
60
TENURE
8.8 yrs

Marianne Lambertson

TITLE
Vice President of Communications & Investor Relations
TENURE
0.6 yrs
Board of Directors Tenure

Average tenure and age of the Celsion board of directors in years:

8
Average Tenure
67
Average Age
  • The tenure for the Celsion board of directors is about average.
Board of Directors

Michael Tardugno

TITLE
Executive Chairman
COMPENSATION
$3M
AGE
67
TENURE
4.5 yrs

Bob Hooper

TITLE
Independent Director
COMPENSATION
$210K
AGE
71
TENURE
8.8 yrs

Frederick Fritz

TITLE
Independent Director
COMPENSATION
$264K
AGE
67
TENURE
7.8 yrs

Andreas Voss

TITLE
Independent Director
COMPENSATION
$158K
AGE
59
TENURE
3.3 yrs

Augustine Chow

TITLE
Independent Director
COMPENSATION
$205K
AGE
65
TENURE
12.1 yrs

Alberto Martinez

TITLE
Independent Director
COMPENSATION
$205K
AGE
68
TENURE
8.3 yrs

David Cheresh

TITLE
Member of Advisory Board

Peter Corry

TITLE
Member of Advisory Board

Mark Dewhirst

TITLE
Member of Advisory Board

Wafik El-Deiry

TITLE
Member of Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Celsion insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
07. Mar 19 Buy Frederick Fritz Individual 06. Mar 19 06. Mar 19 6,700 €1.88 €12,606
30. Oct 18 Buy Michael Tardugno Individual 29. Oct 18 29. Oct 18 7,500 €1.81 €13,602
03. Oct 18 Buy Robert Hooper Individual 02. Oct 18 03. Oct 18 10,000 €2.34 €23,425
21. Sep 18 Buy Frederick Fritz Individual 20. Sep 18 20. Sep 18 5,000 €2.30 €11,490
15. Aug 18 Buy Frederick Fritz Individual 15. Aug 18 15. Aug 18 2,750 €2.09 €5,757
15. Aug 18 Buy Frederick Fritz Individual 15. Aug 18 15. Aug 18 2,750 €2.13 €5,854
X
Management checks
We assess Celsion's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Celsion has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Celsion Corporation, a development stage oncology drug company, focuses on the development and commercialization of directed chemotherapy, DNA-mediated immunotherapy, and RNA based therapy products for the treatment of cancer. The company’s lead product includes ThermoDox, a liposomal encapsulation of doxorubicin that is in Phase III clinical trials for primary liver cancer; and under Phase II clinical trials to treat recurrent chest wall breast cancer. It is also developing GEN-1, a DNA-based immunotherapeutic product for the localized treatment of ovarian and brain cancers. Celsion Corporation was founded in 1982 and is headquartered in Lawrenceville, New Jersey.

Details
Name: Celsion Corporation
CBOC
Exchange: DB
Founded: 1982
$41,448,164
19,562,020
Website: http://www.celsion.com
Address: Celsion Corporation
997 Lenox Drive,
Suite 100,
Lawrenceville,
New Jersey, 08648,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM CLSN Common Stock Nasdaq Capital Market US USD 05. Mar 1985
DB CBOC Common Stock Deutsche Boerse AG DE EUR 05. Mar 1985
LSE 0HUZ Common Stock London Stock Exchange GB USD 05. Mar 1985
Number of employees
Current staff
Staff numbers
29
Celsion employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 22:04
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/04/01
Last earnings filing: 2019/03/29
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.